Clinical

An estimated 1 in 4 patients treated with durvalumab and chemotherapy (gemcitabine plus cisplatin) was alive at 2 years compared with 1 in 10 treated with chemotherapy alone, with these results contributing to the FDA's approval of the first immunotherapy to treat these cancers.

The case emphasizes the importance for clinician awareness of the potential for rare immune-mediated disorders, including acquired hemophilia A (AHA), following allogeneic hematopoietic stem cell transplantation (HSCT).

A new therapeutic paradigm has heightened the need for meaningful measures of assessing patients.

The management of myeloproliferative neoplasms (MPNs) in adolescent and young adult (AYA) patients is currently similar to that of older patients. However, comprehensive research is needed to form guidelines for this younger population.

Experts discuss improving outcomes for patients with heart failure through appropriate and timely switches to ARN inhibitors.

The panel explores clinical evaluations, such as the PROVE-HF study and PARADIGM-HF trial.

Frank J. Palella Jr, MD, and Carl Schmid continue the discussion of patient selection for long-acting injectable PrEP and its cost effectiveness in comparison with other PrEP modalities.

Dr Lynne H. Milgram starts the conversation on choosing the right candidate for long-acting injectable PrEP, as well as how findings show it is cost effective.

Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo.

Comorbidities and disease states associated with vitiligo are explored by a panel of key opinion leaders.

Post hoc analyses of the phase 3 PEGASUS trial found that clinical and hematological improvements were associated with better patient-reported fatigue and physical function outcomes in paroxysmal nocturnal hemoglobinuria, for an overall bettering of health-related quality of life (HRQOL).

Jeffrey Feldman, MD, details the clinical burden of CKD management, and Bertram Pitt, MD, discusses the impact CKD can have on patients at risk for cardiovascular disease.

Paul Sapia, MHA, explains the economic burden of treating chronic kidney disease.

The findings mean it may be feasible to use adult systemic lupus nephritis (SLE) trial data to reduce the data needed for pediatric indications.

With evidence lacking on the role of inflammation in nasal polyposis (NP), this study investigated the role of 2 potential biomarkers in the nasal secretions of patients who have NP concomitant with aspirin-exacerbated respiratory disease.

This new study investigated risk factors for cardiovascular disease, including heart failure, among hospitalized patients with a recent history of methamphetamine use and priority patient populations to target.

Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.

The real-world study adds to previous randomized controlled trial findings suggesting that shorter courses of antibiotic therapy can be sufficient for hospitalized patients with mild or moderate community-acquired pneumonia.

New research suggests Nestin expression can help distinguish combined hepatocellular-cholangiocarcinomas (CCAs) from hepatocellular carcinomas and intrahepatic cholangiocarcinomas.

Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.

In the phase 3 trial, Pfizer’s vaccine was 85.7% effective against respiratory syncytial virus (RSV) defined by 3 or more symptoms among older adults.

David Epstein, MD, MBA, an independent consultant, gives an overview of payer considerations surrounding vitiligo.

Vitiligo’s effects on clinical burden and patient quality of life are addressed by Brett King, MD, PhD, and David Rosmarin, MD.

A clinician, advocate, and payer provide their expert knowledge on the multiple modalities of PrEP therapy and how some can be more beneficial than others.

Frank J. Palella, Jr discusses cabotegravir, a recently approved injectable PrEP medication, that was test in the HTPN 083 and -084 trials.